necitumumab

{
  "id": "MLC-T-ONC-005709",
  "term": "necitumumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with gemcitabine and cisplatin to treat squamous non-small cell lung cancer that has spread to other parts of the body. It is used in patients whose cancer has not been treated with other anticancer therapy. It is also being studied in the treatment of other types of cancer. Necitumumab binds to a protein called epidermal growth factor receptor (EGFR), which is found on some types of cancer cells. Blocking this protein may help keep cancer cells from growing. Necitumumab is a type of monoclonal antibody. Also called Portrazza.",
    "A fully human IgG1 monoclonal antibody directed against the epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Necitumumab binds to and blocks the ligand binding site of EGFR, thereby preventing the activation and subsequent dimerization of the receptor. This may lead to an inhibition of EGFR-dependent downstream pathways and so inhibition of EGFR-dependent tumor cell proliferation and metastasis. EGFR, a member of the epidermal growth factor family of extracellular protein ligands, may be overexpressed on the cell surfaces of various tumor cell types."
  ],
  "synonyms": [
    "Portrazza",
    "anti-EGFR monoclonal antibody IMC-11F8"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/necitumumab/"
}